Pure undiluted cannabis essential oil is a green concentrated, sticky, resinous substance that is considered highly volatile, and its component parts are very powerful, including monoterpenes, sesquiterpenes, and other highly active organic compounds. It is extracted by steam distillation from the flowers and upper leaves of cannabis plants, which are in the Cannabis genus. The essential oil is primarily made and distributed from France and various other European countries, but its exportation is somewhat limited by, as mentioned above, the legal ramifications of what cannabis essential oil is derived from.
This is a critical area for new research. While there is preliminary evidence that CBD may have therapeutic value for a number of conditions, we need to be careful to not get ahead of the evidence. Ninety-five percent of drugs that move from promising preclinical findings to clinical research do not make it to market. The recently announced elimination of the PHS review of non-federally funded research protocols involving marijuana is an important first step to enhance conducting research on marijuana and its components such as CBD. Still, it is important to try to understand the reasons for the lack of well-controlled clinical trials of CBD including: the regulatory requirements associated with doing research with Schedule I substances, including a requirement to demonstrate institutional review board approval; and the lack of CBD that has been produced under the guidance of Current Good Manufacturing Processes (cGMP) – required for testing in human clinical trials – available for researchers. Furthermore, the opportunity to gather important information on clinical outcomes through practical (non-randomized) trials for patients using CBD products available in state marijuana dispensaries is complicated by the variable quality and purity of CBD from these sources.
CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex. It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). Sativex was also given a conditional Notice of Compliance (NOC/c) for use as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis and as adjunctive analgesic treatment for moderate to severe pain in adult patients with advanced cancer .
Now let’s compare to an “average” concentration of THC in some of the cannabis flowers that we use to make our oil (we’re using whole numbers to make it easy to follow). For the sake of argument, let's say that we use flowers with a potency of 10% THC (on a fully decarboxylated basis). This means that each gram of cannabis flowers contains 100 mg THC (1 gram = 1000 mg, 1000 mg x 0.1 = 100 mg). Theoretically we would have to use 10 grams of flowers to equal 1000 mg of THC (which is what we have in our 50 mL bottles). But this process is not 100% efficient (nothing ever is!). So we have to account for extraction efficiency during cannabis resin production, plus losses from decarboxylation, dilution, and packaging.
The carrier oils used to create our products will solidify and go cloudy in cold temperatures. It is important to remember that this will not change the quality of the oil or alter its effects. If your oil has turned solid or gone cloudy, place the sealed bottle in a container of hot water until it melts and then mix thoroughly by inverting the bottle 5-10 times.